LISATA THERAPEUTICS, INC. 8-K

What Happened

• Lisata Therapeutics (LSTA) filed an 8-K on May 29, 2026 announcing an amendment to its previously disclosed merger agreement with Kuva Labs Inc. and its acquisition subsidiary. The amendment reduces the immediate cash offer from $5.00 to $4.00 per share and replaces the prior contingent value right (CVR) with a new non-tradeable CVR that can pay up to $3.00 per CVR upon achievement of specified clinical and regulatory milestones tied to certepetide (formerly LSTA1 / CEND-1).
• Key timetable changes: the tender offer start date was moved to June 1, 2026 (from May 29, 2026) and the Merger Agreement “Outside Date” was extended from July 1, 2026 to July 6, 2026. The tender offer has not yet commenced; related Schedule TO and Schedule 14D‑9 materials will be filed if and when the offer is launched.

Key Details

• Cash consideration: $4.00 per Lisata common share (net to seller, without interest, subject to tax withholding).
• CVR payout structure: one non-tradeable CVR per share, with up to $3.00 aggregate per CVR paid as two milestone payments — $1.25 (First Milestone) and $1.75 (Second Milestone).
• Milestone triggers:
  • First Milestone: completion of enrollment (or ≥90% of target enrollment) or termination by sponsor of a Phase 2a double-blind, randomized proof‑of‑concept trial LSTA1-GBM-2A in newly diagnosed GBM; payment due the later of Dec 15, 2026 or 45 days after achievement.
  • Second Milestone: filing or formal acceptance for review by a governmental body of an NDA (or analogous foreign submission) for the CVR Product; payment due 45 days after achievement.
• Other CVR terms: CVRs are non-tradable; unpaid First Milestone amounts accrue interest at the lesser of (i) 10% p.a., (ii) SOFR + 5% p.a., or (iii) the maximum legal rate. Milestone payments are subject to a cutoff (including the earlier of payment mailing, the 7th anniversary of closing, or termination of the CVR Agreement).

Why It Matters

• For investors, the amendment shifts $1.00 of immediate cash into contingent, development‑dependent payments — reducing upfront cash certainty while increasing upside tied to clinical and regulatory progress of certepetide. Because the CVRs are non‑tradeable and milestone‑dependent, they may have limited liquidity and could pay nothing if milestones are not met.
• The change affects the risk/return profile of the proposed merger: shareholders who want immediate cash receive less now; holders who believe in the drug’s clinical success preserve upside via the CVR. The filing reiterates that the tender offer materials (Schedule TO) and Lisata’s recommendation (Schedule 14D‑9) will provide full details if the offer is commenced. Investors should review those documents and Lisata’s SEC filings before making decisions.